Olanzapine

證據等級: L5

預測適應症: 3 個

Olanzapine: From Schizophrenia / Bipolar Disorder to Benign Paroxysmal Torticollis of Infancy

One-Sentence Summary

Olanzapine is a well-established second-generation (atypical) antipsychotic, approved internationally for schizophrenia and bipolar disorder. The TxGNN model predicts it may be relevant to Benign Paroxysmal Torticollis of Infancy (BPTI), with 0 clinical trials and 0 publications currently supporting this direction. Importantly, mechanistic review suggests this is likely a reverse signal — olanzapine’s dopamine D2 antagonism is a known cause of drug-induced torticollis, not a treatment for it.

Quick Overview

Item	Content
Original Indication	Schizophrenia; Bipolar Disorder (NL authorisation data not retrieved — see note below)
Predicted New Indication	Benign Paroxysmal Torticollis of Infancy
TxGNN Prediction Score	99.54%
Evidence Level	L5
NL Market Status	Not registered (data may be incomplete — see note below)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this Evidence Pack. Based on established pharmacological knowledge, Olanzapine is a multi-receptor antagonist with particularly strong affinity for dopamine D2 receptors and serotonin 5-HT2A receptors, as well as histamine H1, muscarinic, and alpha-adrenergic receptors. Its proven therapeutic role spans schizophrenia, acute bipolar mania, and — in combination with fluoxetine (as Symbyax) — bipolar depression.

Benign Paroxysmal Torticollis of Infancy (BPTI) is classified under the ICHD-3 as a childhood migraine variant. It presents as recurrent, self-limiting episodes of head tilt in infants and toddlers, with a proposed pathophysiology involving ion channel dysfunction and the trigeminovascular system — a mechanism that is distinct from the dopaminergic targets of olanzapine.

Critical mechanistic concern: Rather than a genuine therapeutic signal, this TxGNN prediction is most likely a reverse mechanistic artefact. Acute drug-induced dystonia and torticollis are well-recognised adverse effects of D2 receptor antagonists, including olanzapine. The model’s high score almost certainly reflects knowledge graph proximity — the “torticollis” symptom node is shared between BPTI and the adverse effect profile of olanzapine — rather than any positive treatment relationship. Applying olanzapine in BPTI would be mechanistically contraindicated and could actively worsen the condition.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Netherlands Market Information

No CBG-MEB marketing authorisations for Olanzapine were retrieved in this dataset. This is likely a data collection gap: Olanzapine (brand name Zyprexa and multiple generic equivalents) is a centrally authorised medicinal product in the European Union and is expected to be available in the Netherlands under EMA authorisation. Prescribers should verify the current status directly via the CBG-MEB product register or the EMA European Public Assessment Report (EPAR).

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for complete safety information. In particular, given the mechanistic concern above, the sections on extrapyramidal adverse effects, acute dystonia, and use in paediatric populations are especially relevant to any assessment of this predicted indication.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high score based on knowledge graph proximity via a shared “torticollis” symptom node, but mechanistic analysis identifies this as a reverse signal: olanzapine-induced acute dystonia/torticollis is a known adverse drug reaction, making the drug more likely to cause the condition than treat it. There is no supporting clinical trial or literature evidence. This candidate should not advance further under the current framing.

To proceed, the following is needed:

Independent mechanistic review by a clinical pharmacologist to formally document the reverse signal and close this candidate
Retrieval of NL CBG-MEB / EMA authorisation data to correct the market status record for Olanzapine
Retrieval of the full SmPC (including extrapyramidal warnings and paediatric contraindications) to complete the safety profile
Completion of MOA data from DrugBank (flagged as DG002) to enable robust mechanistic analysis for all predicted indications
Consideration of the Rank 2 (Agoraphobia, L3) and Rank 3 (Dysthymic Disorder, L3) predicted indications, which carry more plausible mechanistic rationale and existing literature, and may be more productive repurposing candidates for further evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.